These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17943249

  • 1. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C.
    Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
    [Abstract] [Full Text] [Related]

  • 2. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
    Steinman L, Zamvil SS.
    Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
    [Abstract] [Full Text] [Related]

  • 3. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Garay L, Gonzalez Deniselle MC, Gierman L, Meyer M, Lima A, Roig P, De Nicola AF.
    Neuroimmunomodulation; 2008 Nov; 15(1):76-83. PubMed ID: 18667803
    [Abstract] [Full Text] [Related]

  • 4. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Humle Jorgensen S, Sorensen PS.
    J Neurol Sci; 2005 Jun 15; 233(1-2):61-5. PubMed ID: 15949496
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.
    Stojkov D, Lavrnja I, Pekovic S, Dacic S, Bjelobaba I, Mostarica-Stojkovic M, Stosic-Grujicic S, Jovanovic S, Nedeljkovic N, Rakic L, Stojiljkovic M.
    J Neurol Sci; 2008 Apr 15; 267(1-2):76-85. PubMed ID: 17996253
    [Abstract] [Full Text] [Related]

  • 6. Amelioration of acute and relapsing stages of the experimental allergic encephalomyelitis by cobra toxins.
    Mohamed A, Reid PF, Raymond L, Dufan T.
    Biomed Sci Instrum; 2006 Apr 15; 42():399-404. PubMed ID: 16817641
    [Abstract] [Full Text] [Related]

  • 7. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.
    Sriram S, Steiner I.
    Ann Neurol; 2005 Dec 15; 58(6):939-45. PubMed ID: 16315280
    [Abstract] [Full Text] [Related]

  • 8. Lessons from multiple sclerosis: models, concepts, observations.
    Wekerle H.
    Ann Rheum Dis; 2008 Dec 15; 67 Suppl 3():iii56-60. PubMed ID: 19022815
    [Abstract] [Full Text] [Related]

  • 9. Antioxidant therapy in multiple sclerosis.
    Mirshafiey A, Mohsenzadegan M.
    Immunopharmacol Immunotoxicol; 2009 Dec 15; 31(1):13-29. PubMed ID: 18763202
    [Abstract] [Full Text] [Related]

  • 10. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis.
    't Hart BA, Hintzen RQ, Laman JD.
    Neurodegener Dis; 2008 Dec 15; 5(1):38-52. PubMed ID: 18075274
    [Abstract] [Full Text] [Related]

  • 11. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Reichardt HM, Gold R, Lühder F.
    Expert Rev Neurother; 2006 Nov 15; 6(11):1657-70. PubMed ID: 17144780
    [Abstract] [Full Text] [Related]

  • 12. Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis.
    Petry KG, Boullerne AI, Pousset F, Brochet B, Caillé JM, Dousset V.
    Pathol Biol (Paris); 2000 Feb 15; 48(1):47-53. PubMed ID: 10729911
    [Abstract] [Full Text] [Related]

  • 13. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus).
    't Hart BA, Massacesi L.
    J Neuropathol Exp Neurol; 2009 Apr 15; 68(4):341-55. PubMed ID: 19337065
    [Abstract] [Full Text] [Related]

  • 14. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis.
    Ransohoff RM.
    Trends Immunol; 2006 Apr 15; 27(4):167-8. PubMed ID: 16513422
    [No Abstract] [Full Text] [Related]

  • 15. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators.
    Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM.
    J Neurol Sci; 2007 Aug 15; 259(1-2):79-84. PubMed ID: 17382965
    [Abstract] [Full Text] [Related]

  • 16. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Achiron A, Miron S.
    Mult Scler; 2000 Oct 15; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777
    [Abstract] [Full Text] [Related]

  • 17. Thalidomide derivatives for the treatment of neuroinflammation.
    Contino-Pépin C, Parat A, Patinote C, Roscoe WA, Karlik SJ, Pucci B.
    ChemMedChem; 2010 Dec 03; 5(12):2057-64. PubMed ID: 20936622
    [Abstract] [Full Text] [Related]

  • 18. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis.
    Tafreshi AP, Ahmadi A, Ghaffarpur M, Mostafavi H, Rezaeizadeh H, Minaie B, Faghihzadeh S, Naseri M.
    Phytother Res; 2008 Aug 03; 22(8):1083-6. PubMed ID: 18570265
    [Abstract] [Full Text] [Related]

  • 19. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
    Contino-Pépin C, Parat A, Périno S, Lenoir C, Vidal M, Galons H, Karlik S, Pucci B.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):878-81. PubMed ID: 19103485
    [Abstract] [Full Text] [Related]

  • 20. Glucocorticoids in the control of neuroinflammation.
    Tischner D, Reichardt HM.
    Mol Cell Endocrinol; 2007 Sep 15; 275(1-2):62-70. PubMed ID: 17555867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.